Rocket Pharmaceuticals
RCKT
92 hedge funds and large institutions have $555M invested in Rocket Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 20 reducing their positions, and 17 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.83% less ownership
Funds ownership: 97.57% → 94.74% (-2.8%)
4% less funds holding
Funds holding: 96 → 92 (-4)
20% less call options, than puts
Call options by funds: $340K | Put options by funds: $425K
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
25% less capital invested
Capital invested by funds: $736M → $555M (-$181M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.4M |
| 2 |
DM
Deerfield Management
New York
|
+$7.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$5.22M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.34M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32.4M |
| 2 |
BM
Bridger Management
New York
|
-$18.7M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.8M |
| 4 |
Millennium Management
New York
|
-$6.61M |
| 5 |
AG
Artal Group
Luxembourg
|
-$5.4M |
RCKT Hedge Fund Activity: Q3 2019 in Review
92 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2019, worth a combined $555M — down 25% from $736M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RCKT and 13 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 39 added.
The largest buyer was Wellington Management Group, adding an estimated $17.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $32.4M sold.
- 92 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2019, down from 96 in Q2 2019.
- Funds reported $555M of Rocket Pharmaceuticals stock for Q3 2019, down 25% quarter-over-quarter.
- 13 funds opened new Rocket Pharmaceuticals positions in Q3 2019 and 17 closed out, a net change of -4 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2019 was Wellington Management Group, an estimated $17.4M added.
- The largest Rocket Pharmaceuticals seller in Q3 2019 was Adage Capital Partners, an estimated $32.4M sold.
Based on aggregated 13F filings for Q3 2019.